PDL BioPharma

PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities. Intellectual Property Patents The company has been issued patents in the United States and elsewhere, covering the humanization of antibodies, which are referred to as its Queen et al. patents.The company was founded as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later...

PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat

PDLI is liquidating, it should delist from the NASDAQ on December 31, 2020. Patient investors can ultimately expect a return of approximately 40% based on net assets.

PDL BioPharma Liquidation May Offer 40% Upside For Patient Investors Comfortable With Illiquidity

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2020 Results - Earnings Call Transcript

Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06.

Recap: PDL BioPharma Q3 Earnings

INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization...

PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the third quarter ended September 30, 2020 and provided an update on key strategic and operational initiatives. The distribution of LENSAR common stock to stockholders of PDL BioPharma, Inc. (“PDL”) (Nasdaq: PDLI) took place on October 1, 2020, and LENSAR

LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update

INCLINE VILLAGE, Nev., Nov. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11, 2020. PDL will issue its third...

PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update

PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

PDL BioPharma Enters Oversold Territory

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the completion of its spin-off from PDL BioPharma, Inc. (NASDAQ: PDLI) (“PDL”). Beginning today, LENSAR shares will commence “regular-way” trading on the NASDAQ Stock Market. The distribution of LENSAR common stock took place on October 1, 2020. PDL stockholders received 0.0758

LENSAR, Inc. Begins Trading on NASDAQ

INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital

INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation

INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024

PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q2 2020 Results - Earnings Call Transcript

INCLINE VILLAGE, Nev., Aug. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma Reports 2020 Second Quarter Financial Results

INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q1 2020 Results - Earnings Call Transcript

PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock?

Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma, Inc. (PDLI) CEO Dominique Monnet on Q4 2019 Results - Earnings Call Transcript

The company announced the completion of a strategic review with plans that could mean good news for investors.

Why Shares of PDL BioPharma Are Soaring Today

Why Is PDL BioPharma (PDLI) Up 5.3% Since Last Earnings Report?

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well.

PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales

PDL BioPharma's (PDLI) CEO Dominique Monnet on Q3 2019 Results - Earnings Call Transcript

A letter from an activist investor to the company's board of directors is lighting a fire beneath this healthcare stock.

News for PDL BioPharma Stock (PDLI)